Aeolus Pharmaceuticals, Inc. (AOLS) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAeolus Pharmaceuticals, Inc. (AOLS) trades at $0.0001. Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company developing catalytic antioxidant compounds for biodefense, fibrosis, oncology, infectious, and central nervous system diseases. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for AOLS: AOLS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Aeolus Pharmaceuticals, Inc. (AOLS) Healthcare & Pipeline Overview
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical entity focused on advancing a platform of catalytic antioxidant compounds for critical unmet needs across biodefense, neurological, and infectious diseases. The company's pipeline includes lead asset AEOL 10150, currently in early clinical development for radiation and chemical agent countermeasures, positioning it in specialized therapeutic markets.
What Is the Investment Thesis for AOLS?
Aeolus Pharmaceuticals, Inc. presents an investment thesis centered on its specialized biopharmaceutical pipeline, particularly its catalytic antioxidant compounds targeting high-need areas like biodefense and neurodegenerative diseases. The lead compound, AEOL 10150, having completed two Phase I clinical trials, represents a significant value driver, addressing acute radiation syndrome and chemical agent exposure, markets often supported by government funding and contracts. The company's additional compounds, AEOL 11114B, AEOL 11203, and AEOL 11207, targeting Parkinson's disease, and AEOL 20415 for infectious diseases, offer diversification and address substantial global health challenges. While the company's extremely low market capitalization of $0.00B and negative profit margin of -171.4% indicate significant financial risk and an early-stage, R&D-intensive profile, successful advancement of its pipeline through clinical trials and securing strategic partnerships or government contracts could serve as key catalysts for value creation. The focused therapeutic approach on unmet needs, leveraging a unique antioxidant platform, positions Aeolus Pharmaceuticals for potential future growth, contingent on clinical and regulatory successes.
Based on FMP financials and quantitative analysis
AOLS Key Highlights
Market capitalization of $0.00B, reflecting an early-stage development company with a limited public valuation.
- Profit margin of -171.4%, indicative of a company in the research and development phase with no current revenue-generating products.
- Gross margin of -38.8%, further emphasizing the absence of product sales and the costs associated with R&D activities.
- Beta of -5.55, suggesting a highly inverse relationship with the broader market, which is unusual and may reflect low liquidity or specific trading dynamics.
- Operates with a lean team of 4 employees, indicating a focused, small-scale operation primarily dedicated to drug development.
Who Are AOLS's Competitors?
AOLS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.91 | -3.54% | — | |
| APUS Apimeds Pharmaceuticals US, Inc. | $4.59 | +42.55% | $7.59M | — |
| BFRI Biofrontera Inc. | $0.89 | -12.23% | $11.4M | — |
| COSM COSM | $0.35 | -9.03% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.27 | -4.94% | $20.9M | — |
| AYTU Aytu BioPharma, Inc. | $2.04 | -1.45% | $21.9M | — |
| TXMD TherapeuticsMD, Inc. | $2.01 | -1.95% | $24.0M | — |
| CPHI CPHI | $0.65 | -0.61% | $27.0M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AOLS's Key Strengths?
Focused therapeutic pipeline addressing high unmet medical needs in biodefense and neurodegenerative diseases.
- Proprietary platform of catalytic antioxidant compounds with potential for broad applications.
- Lead compound, AEOL 10150, has completed two Phase I clinical trials, demonstrating early clinical progress.
- Potential for government funding and contracts for biodefense countermeasures.
What Are AOLS's Weaknesses?
Extremely low market capitalization ($0.00B) and negative profitability (-171.4% profit margin) indicating significant financial instability.
- Early-stage clinical pipeline with no commercialized products, leading to high R&D costs and no revenue.
- Small operational team of 4 employees, which may limit the scope and speed of development.
- OTC Other listing, implying limited transparency, liquidity, and investor access.
What Are the Key Risks for AOLS?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Significant financial risk due to extremely low market capitalization ($0.00B), negative profit margins, and the absence of revenue-generating products.
- High risk of clinical trial failures for its pipeline compounds, which could lead to substantial financial losses and delays in drug development.
- Challenges in securing adequate funding for ongoing and future research and development activities, potentially leading to dilution or cessation of programs.
- Intense competition within the biopharmaceutical industry from larger, well-funded companies with more extensive R&D resources and established market presence.
- Regulatory hurdles and lengthy approval processes inherent in drug development, which can delay market entry and increase costs.
What Are AOLS's Competitive Advantages?
- Proprietary platform of novel catalytic antioxidant compounds with unique mechanisms of action.
- Early-stage clinical data for lead compound AEOL 10150 in specialized biodefense applications.
- Focused pipeline addressing high unmet medical needs in niche therapeutic areas like acute radiation syndrome and Parkinson's disease.
- Intellectual property surrounding its specific chemical entities and their therapeutic uses.
What Does AOLS Do?
Aeolus Pharmaceuticals, Inc., founded in 1994 and headquartered in Mission Viejo, California, operates as a biopharmaceutical company dedicated to the development of a proprietary platform of novel catalytic antioxidant compounds. These compounds are engineered for a broad spectrum of therapeutic applications, including biodefense, fibrosis, oncology, infectious diseases, and central nervous system disorders within the United States. The company's strategic focus encompasses developing medical countermeasures against severe threats such as nuclear, radiological, and chemical weapons, alongside treatments for various respiratory, central nervous system, and oncological conditions. A cornerstone of Aeolus Pharmaceuticals' pipeline is AEOL 10150, its lead compound, which has successfully completed two Phase I clinical trials. This compound is specifically being developed to address the pulmonary sub-syndrome of acute radiation syndrome, a critical area given its potential as a medical countermeasure. Furthermore, AEOL 10150 is being explored for its utility against exposure to chemical vesicants and nerve agents, highlighting its potential significance in national security and emergency preparedness. Beyond its biodefense initiatives, Aeolus Pharmaceuticals is actively advancing several other compounds, including AEOL 11114B, AEOL 11203, and AEOL 11207, which are under development for the treatment of Parkinson's disease, a neurodegenerative disorder with significant unmet medical needs. The company's pipeline also extends to infectious diseases, with AEOL 20415 being developed to combat various pathogens. With a lean operational structure, evidenced by its four employees, Aeolus Pharmaceuticals maintains a concentrated effort on its research and development activities, aiming to bring its innovative catalytic antioxidant technology from early-stage development to potential clinical application.
What Products and Services Does AOLS Offer?
- Develops a platform of novel catalytic antioxidant compounds.
- Focuses on biodefense applications, including medical countermeasures against nuclear, radiological, and chemical weapons.
- Researches treatments for fibrosis, oncology, infectious, and central nervous system diseases.
- Advances AEOL 10150, a lead compound, through clinical trials for acute radiation syndrome and chemical agent exposure.
- Develops compounds like AEOL 11114B, AEOL 11203, and AEOL 11207 for Parkinson's disease.
- Explores AEOL 20415 for the treatment of various infectious diseases.
- Operates as a biopharmaceutical company based in Mission Viejo, California.
How Does AOLS Make Money?
- Primarily an R&D-focused biopharmaceutical company, investing in the discovery and clinical development of novel drug candidates.
- Future revenue generation is anticipated through the commercialization of approved drugs, potentially via direct sales or licensing agreements with larger pharmaceutical partners.
- Potential for government contracts and grants, especially for biodefense-related compounds like AEOL 10150, which could provide non-dilutive funding.
- Relies on intellectual property protection (patents) for its proprietary catalytic antioxidant compounds to secure market exclusivity upon approval.
What Industry Does AOLS Operate In?
Aeolus Pharmaceuticals, Inc. operates within the highly specialized and competitive biopharmaceutical industry, specifically within the Drug Manufacturers - Specialty & Generic segment. This sector is characterized by intensive research and development, long product development cycles, and significant regulatory hurdles. The company's focus on catalytic antioxidant compounds for biodefense, neurodegenerative diseases, and infectious diseases positions it within niche markets that often have high unmet medical needs and potential for orphan drug designations or government funding. The broader biopharmaceutical market is driven by demographic shifts, increasing prevalence of chronic diseases, and technological advancements. However, competition is fierce, with numerous large pharmaceutical companies and smaller biotechs vying for market share. Aeolus Pharmaceuticals' early-stage pipeline means it is not yet competing on commercialized products but rather on the scientific merit and clinical progress of its novel compounds, particularly in areas like acute radiation syndrome where specific medical countermeasures are critical.
Who Are AOLS's Key Customers?
- Future patients suffering from acute radiation syndrome, chemical agent exposure, Parkinson's disease, or infectious diseases.
- Government agencies (e.g., Department of Defense, BARDA) for biodefense medical countermeasures.
- Potentially larger pharmaceutical companies seeking to license or acquire novel drug candidates for their portfolios.
- Healthcare providers and institutions that would prescribe or administer approved therapies.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
Return on assets is -85.4%, showing how much profit it generates from its asset base. A current ratio of 4.25 indicates the company holds enough short-term assets to cover its near-term obligations.
Company Profile
Aeolus Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Mission Viejo, US. The company is led by CEO Christopher Stanley. AOLS has traded publicly since 1996.
Financial Health
Aeolus Pharmaceuticals, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Insider Activity
12 transactions · 0 purchases, 0 sales, 12 other transactions · 6 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
AOLS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
AOLS Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Aug 20, 2019
AOLS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for AOLS.
Price Targets
Wall Street price target analysis for AOLS.
AOLS MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for AOLS; grades run from A+ (80-100) to F (below 30).
Leadership: Christopher Stanley
Chief Executive Officer
Christopher Stanley serves as the Chief Executive Officer of Aeolus Pharmaceuticals, Inc., leading the company's strategic direction and operational execution. While specific details regarding his extensive career history, educational background, and previous executive roles are not publicly disclosed, his current role involves managing the company's lean team of four employees. In this capacity, Mr. Stanley is responsible for overseeing the development of Aeolus's platform of novel catalytic antioxidant compounds, guiding the company's efforts in biodefense, fibrosis, oncology, infectious, and central nervous system diseases. His leadership is critical in navigating the complexities of early-stage biopharmaceutical development.
Track Record: Under Christopher Stanley's leadership, Aeolus Pharmaceuticals has focused its resources on advancing its specialized pipeline, notably with the lead compound AEOL 10150 completing two Phase I clinical trials. His strategic decisions have centered on targeting high-unmet-need areas such as acute radiation syndrome and Parkinson's disease. While specific milestones beyond clinical trial progression are not detailed, his tenure is marked by the continued pursuit of the company's drug development programs with a small, dedicated team.
AOLS OTC Market Information
Aeolus Pharmaceuticals, Inc. trades on the OTC market under the 'OTC Other' tier. This classification signifies that the company does not meet the disclosure requirements for OTCQX or OTCQB, which are higher tiers with more stringent reporting standards. Companies in the 'OTC Other' tier typically have limited public disclosure, which can make it challenging for investors to access comprehensive financial and operational information. Unlike companies listed on major exchanges like NYSE or NASDAQ, which adhere to strict listing standards including minimum share prices, market capitalization, and regular SEC filings, 'OTC Other' companies operate with significantly less oversight and transparency, often appealing to speculative investors willing to accept higher risk.
- OTC Tier: OTC Other
- Limited public disclosure and transparency, making it difficult to assess financial health and operational performance.
- Extremely low liquidity, leading to wide bid-ask spreads and difficulty in executing trades without significant price impact.
- Higher susceptibility to manipulation and fraud due to less regulatory oversight compared to major exchanges.
- Difficulty in obtaining reliable and timely information, increasing the risk of uninformed investment decisions.
- Potential for delisting or further restrictions if disclosure standards are not met or if the company ceases operations.
- Verify the company's current operational status and any recent news or press releases through alternative sources.
- Attempt to locate any available financial statements or corporate updates, even if not formally filed.
- Research the background and track record of management beyond what is publicly available.
- Assess the viability and market potential of the company's lead compounds and intellectual property.
- Understand the current shareholder structure and any major institutional or insider holdings.
- Evaluate the company's cash burn rate and potential need for future financing, given its R&D focus.
- Consult with legal counsel regarding the specific risks associated with investing in 'OTC Other' securities.
- The company has a stated headquarters in Mission Viejo, California, indicating a physical presence.
- It was founded in 1994, suggesting a long-standing, albeit early-stage, commitment to its mission.
- The lead compound, AEOL 10150, has completed two Phase I clinical trials, indicating tangible progress in drug development.
- The company's focus on specific therapeutic areas like biodefense and Parkinson's disease suggests a defined scientific strategy.
- The existence of a named CEO, Christopher Stanley, provides a point of contact for leadership.
What Investors Ask About Aeolus Pharmaceuticals, Inc. (AOLS) — Healthcare
What are the implications of Aeolus Pharmaceuticals, Inc. trading on the OTC market?
Aeolus Pharmaceuticals, Inc.'s listing on the OTC market, specifically in the 'OTC Other' tier, carries several implications for investors. This tier signifies minimal public disclosure requirements compared to major exchanges or even higher OTC tiers, leading to an 'Unknown' disclosure status.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information regarding CEO's detailed background and track record is limited to publicly available data.
- Specific details on clinical trial timelines beyond 'Phase I completed' are not provided in the source data.
- Financial metrics are based on provided summary data and do not include full financial statements.